Site icon pharmaceutical daily

Cancer Immunotherapy Markets, 2023 – ResearchAndMarkets.com

BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Cancer
Immunotherapy Markets – Market Forecasts for Immuno-Oncology
Therapeutics Including Executive and Consultant Guides and a Complete
Listing of Active Company Summaries 2019 to 2023” report has
been added to ResearchAndMarkets.com’s offering.

A revolution in cancer therapy is underway. New therapy based on using
the body’s natural immune defenses is having unprecedented success. This
is a complex area but our readable reports help you understand it, both
the technology and the opportunity. The technologies and opportunities
are explored. Over one hundred companies are profiled.

The technology is moving faster than the market. Already worth billions
the global market is poised for dramatic growth. Is the cure in sight?
The impact on the health care industry is enormous. The report forecasts
the market size out to 2023.

CAR – T Cells? Checkpoint Inhibitors? Cytokines? Find out about the
technology in readily understood terms that explain the jargon. Find the
opportunities and the pitfalls. Understand growth expectations and the
ultimate potential market size.

Key Topics Covered:

1. Introduction and Market Definition

1.1 What is Cancer Immunotherapy?

1.2 Immunotherapy – the looming cure

1.3 Market Definition

1.3.1 Market Size

1.3.2 Currency

1.3.3 Years

1.4 Methodology

1.5 U.S. Medical Market and Pharmaceutical Spending – Perspective

1.5.1 U.S. Expenditures for Pharmaceuticals

2. Immunotherapy – Guide to Immune Technologies

2.1 The Immune System

2.1.1 Innate immune system

2.1.1.1 Surface barriers

2.1.1.2 Inflammation

2.1.1.3 Complement system

2.1.1.4 Cellular barriers

2.1.1.5 Natural killer cells

2.1.2 Adaptive immune system

2.1.2.1 Lymphocytes

2.1.2.2 Killer T cells

2.1.2.3 Helper T cells

2.1.2.4 Gamma delta T cells

2.1.2.5 B lymphocytes and antibodies

2.1.3 Tumor immunology – the immune surveillance system

2.2 Immuno Oncology Technologies

2.2.1 Monoclonal Antibodies

2.2.1.1 Outlook for Monoclonal Antibodies

2.2.1.2 Companies with Monoclonal Antibodies in their Pipeline

2.2.2 Cancer vaccines

2.2.2.1 Outlook for Cancer Vaccines

2.2.2.2 Companies with Cancer Vaccines in their Pipeline

2.2.3 Cytokines

2.2.3.1 Outlook for Cytokines

2.2.3.2 Companies with Cytokines in their Pipeline

2.2.4 Cell Based Therapies

2.2.4.1 Outlook for Cell Based Therapies

2.2.4.2 Companies with Cell Based Therapies in their Pipeline

2.2.5 Inhibitors/Agonists

2.2.5.1 Outlook for Inhibitors/Agonists

2.2.5.2 Companies with Inhibitors/Agonists in their Pipeline

2.2.6 Antibody Drug Conjugates

2.2.6.1 Outlook for Antibody Drug Conjugates

2.2.6.2 Companies with Antibody Drug Conjugates in their Pipeline

2.2.7 Others

2.2.7.1 Outlook for Other Therapeutics

2.2.7.2 Companies with Viral Therapeutics in their Pipeline

2.2.7.3 Companies with Other Therapeutics in their Pipeline

3. Industry Overview

3.1 Market Players – Roles & Impacts

3.1.1 Drug manufacturers – Larger/pharmaceutical

3.1.2 Drug manufacturers – Generic

3.1.3 Contract Research and Manufacturing

3.1.4 In Vitro Diagnostics Industry

3.1.5 Drug Marketing Companies

3.1.6 Biotechnology Companies

3.1.7 Regulatory Bodies

4. Market Trends

4.1 Factors Driving Growth

4.1.1 Outcome potential

4.1.2 Fast tracking

4.1.3 Funding

4.1.4 Technology Environment

4.1.5 Target Solutions

4.2 Factors Limiting Growth

4.2.1 Cost of Treatment

4.2.2 Clinical Trials Role

4.2.3 Combinations

4.2.4 Protocols

4.3 Therapeutic Technology Development

4.3.1 Combinations – Issues and Complexity

4.3.2 Preference for a drug

4.3.3 Problems of Immunity Engineering

4.3.4 The Role of Cost

4.3.5 The Disruption Dynamic

4.3.6 CAR-T Cell Therapy

4.3.7 The Next Five Years

5. Cancer Immunotherapy Recent Developments

5.1 Recent Developments – Importance and How to Use This Section

5.1.1 Importance of These Developments

5.1.2 How to Use This Section

6. Profiles of Key Immunotherapy Companies

6.1 Company Pipelines Analysis

6.1.1 All Companies, Pipeline Activity Summary by Technology and Phases

7. Global Market Size.

7.1 Cancer Immunotherapy Global Market Size by Country

7.2 Cancer Immunotherapy Global Market Size by Technology

7.3 Cancer Immunotherapy Global Market Size by Cancer

8. Global Market by Technology

8.1 Monoclonal Antibody Market

8.2 Cancer Vaccine Market

8.3 Cytokines Market

8.4 Cell Based Market

8.5 Inhibitor Agonist Market

8.6 Other Market

9. Cancer Immunotherapy Market by Cancer Type

9.1 Lung Cancers Market

9.2 Breast Cancers Market

9.3 Blood Cancers Market

9.4 Colorectal Cancers Market

9.5 Prostate Cancers Market

9.6 Other Cancers Market

10. Appendices

10.1 FDA Cancer Drug Approvals by Year

10.2 Clinical Trials Started 2010 to 2016

10.3 Prevalence of Cancer Treatments – 2015

For more information about this report visit https://www.researchandmarkets.com/r/uhnk87

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Oncology
Drugs

Exit mobile version